体内
蛋白质水解
蛋白质降解
计算生物学
功能(生物学)
泛素
药理学
生物
细胞生物学
生物技术
生物化学
基因
酶
作者
Gillian F. Watt,Paul Scott‐Stevens,Lu Gaohua
标识
DOI:10.1016/j.ddtec.2019.02.005
摘要
Proteolysis Targeting Chimeras (PROTACs) are a rapidly expanding new therapeutic modality inducing selective protein degradation and offering the potential of a differentiated pharmacological profile across multiple therapeutic areas. As the repertoire of protein targets and E3 ligases available for incorporation into PROTACs continues to grow, understanding the drug- and system-dependent parameters for PROTACs will be critical for achieving tissue/cell specific pharmacology. The review discusses the current knowledge and future direction of in vivo PROTAC study evaluation. The importance of establishing the quantitative relationship between loss of protein target and biological function in vivo, coupled with building mechanistic PK/PD and ultimately PBPK/PD models, is emphasised with the aim to aid translation from preclinical to clinical space.
科研通智能强力驱动
Strongly Powered by AbleSci AI